Proportion of participants with adverse event · Participants with rosacea
Minocycline 45 mg showed no clear difference in proportion of participants with adverse event compared with minocycline 45 mg + azelaic acid gel (low certainty).
1 finding from 1 review
Physician‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Assessment of erythema or telangiectasia · Participants with rosacea
1 finding from 1 review
Lesion count · Participants with rosacea
1 finding from 1 review
Time needed until improvement · Participants with rosacea
1 finding from 1 review
Duration of remission ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
All‐cause mortality · pulmonary hypertension in neonates
Sildenafil plus iNO showed no clear difference in all‐cause mortality compared with placebo plus iNO (low certainty).
1 finding from 1 review
Length of hospital stay · pulmonary hypertension in neonates
1 finding from 1 review
Participant‐rated global improvement · People with chronic plaque or guttate psoriasis
1 finding from 1 review
Percentage of participants reaching PASI 75 · People with chronic plaque or guttate psoriasis
NB‐UVB plus retinoid showed no clear difference in percentage of participants reaching PASI 75 compared with PUVA plus retinoid (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · People with chronic plaque or guttate psoriasis
1 finding from 1 review
Clearance rate · People with chronic plaque or guttate psoriasis
NB‐UVB plus retinoid showed no clear difference in clearance rate compared with PUVA plus retinoid (low certainty).
1 finding from 1 review
Acute gout attacks · people with chronic gout
Allopurinol showed no clear difference in acute gout attacks compared with placebo (moderate certainty).
1 finding from 1 review
Acute gout attacks · people with chronic gout
Allopurinol showed no clear difference in acute gout attacks compared with benzbromarone (low certainty).
1 finding from 1 review
Proportion achieving target serum urate · people with chronic gout
Allopurinol showed no clear difference in proportion achieving target serum urate compared with benzbromarone (moderate certainty).
1 finding from 1 review
Pain reduction ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Function ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Tophus regression ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Proportion achieving target serum urate · people with chronic gout
Allopurinol probably leads to higher proportion achieving target serum urate compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Allopurinol showed no clear difference in withdrawal due to adverse events compared with benzbromarone (low certainty).
1 finding from 1 review